What must be considered before prescribing sodium valproate?

• A. The patient must sign a valproate risk acknowledgment form completed by two specialists.
• B. Alternative treatments must have been considered first and found to be ineffective or poorly tolerated.
• C. The prescriber must obtain a second opinion from a neurologist.
• D. An MRI must be performed prior to initiation.

Answer: (B)

Because valproate has notable safety concerns, the decision to use it hinges on whether safer or more tolerable alternatives have already been tried and found ineffective or poorly tolerated. This approach reflects a careful risk–benefit assessment: valproate can cause serious teratogenic effects and other adverse reactions, so it should be reserved for situations where other treatments won’t work or aren’t tolerated. In practice, you review the patient’s history with prior therapies, verify lack of adequate response or intolerable side effects, and then proceed with valproate only if there’s a clear clinical need. If it is used, you must implement appropriate risk-management measures, including counseling about pregnancy and contraception for women of childbearing potential and regular monitoring. The other options—mandating a risk acknowledgment from two specialists, requiring a second neurology opinion, or obtaining an MRI before initiation—are not standard prerequisites in all cases and do not address the primary safety-driven rationale for valproate use.